Emery Smith

Whole-genome sequencing of Atacama skeleton shows novel mutations linked with dysplasia
1Institute for Computational Health Sciences, University of California San Francisco, San Francisco, California 94158, USA;
2Roche Sequencing Solutions, Belmont, California 94002, USA;
3Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA;
4Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Stanford University, Stanford,...

Whole-genome sequencing of Atacama skeleton shows novel mutations linked with dysplasia
1Institute for Computational Health Sciences, University of California San Francisco, San Francisco, California 94158, USA;
2Roche Sequencing Solutions, Belmont, California 94002, USA;
3Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA;
4Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Stanford University, Stanford, California 94305, USA;
5International Laboratory for Human Genome Research, National Autonomous University of Mexico (UNAM) Santiago de Querétaro, Querétaro 76230, Mexico;
6Human Immune Monitoring Center and Functional Genomics Facility, Stanford University, Stanford, California 94305, USA;
7Ultra Intelligence Corporation, Boulder, Colorado 80301, USA;
8Department of Pediatric Radiology, Stanford University School of Medicine, Stanford, California 94305, USA

Preclinical and clinical studies have suggested the benefit of using concentrated autologous bone marrow aspirate in bone repair, myocardial infarct and peripheral vascular disease. Bone marrow aspirate is often not sufficient for clinical efficacy in the absence of concentration1,2. This report represents results from an evaluation of GenesisCS device for the concentration of human bone marrow-derived stem cells. Sixty mL of human bone marrow aspirate were concentrated to approximately 5 ml...

Preclinical and clinical studies have suggested the benefit of using concentrated autologous bone marrow aspirate in bone repair, myocardial infarct and peripheral vascular disease. Bone marrow aspirate is often not sufficient for clinical efficacy in the absence of concentration1,2. This report represents results from an evaluation of GenesisCS device for the concentration of human bone marrow-derived stem cells. Sixty mL of human bone marrow aspirate were concentrated to approximately 5 ml with the GenesisCS. Samples of the bone marrow aspirate (BMA) and resulting bone marrow concentrate (BMC) were analyzed for Total Nucleated Cells (TNC), Platelets (Plt), and CD34 positive Hematopoietic Stem Cells (HSC). Yield calculation were done for TNC, Plt and HCS.